NCT02404389 - Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 5, 2015

Primary Completion Date

January 27, 2016

Study Completion Date

January 27, 2016

Conditions

Actinic Keratosis

Interventions

DRUG

Investigational Treatment

Topical application for two treatment cycles with twice daily applications, separated by a 4 week treatment pause and followed by 8 week treatment free follow-up.

DRUG

Active comparator

Topical treatment with Aldara 3 times per week. The group will be open-label, but however blinded to the efficacy assessor, and followed by 8 week treatment free follow-up.

Trial Locations (10)

201

Novartis Investigative Site, Kopavogur

1040

Novartis Investigative Site, Vienna

10098

Novartis Investigative Site, Berlin

10117

Novartis Investigative Site, Berlin

20354

Novartis Investigative Site, Hamburg

53111

Novartis Investigative Site, Bonn

60590

Novartis Investigative Site, Frankfurt

DK-2400

Novartis Investigative Site, Copenhagen NV

01307

Novartis Investigative Site, Dresden

E1 1BB

Novartis Investigative Site, London